Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Annals of Nuclear Medicine
Published in: Annals of Nuclear Medicine 9/2013

01-11-2013 | Original Article

Feasibility and kinetic characteristics of 68Ga-NOTA-RGD PET for in vivo atherosclerosis imaging

Authors: Jin Chul Paeng, Yun-Sang Lee, Jae Sung Lee, Jae Min Jeong, Ki-Bong Kim, June-Key Chung, Dong Soo Lee

Published in: Annals of Nuclear Medicine | Issue 9/2013

Login to get access

Abstract

Objective

In this study, the feasibility and kinetic characteristics of the 68Ga-NOTA-RGD, a recently developed RGD peptide agent, were investigated for atherosclerosis imaging in comparison with 18FDG.

Methods

ApoE−/− mice were fed a high-fat diet for more than 20 weeks. To evaluate the feasibility, tissue uptakes of 68Ga-NOTA-RGD and 18FDG in the major organs were measured and compared between ApoE−/− and control mice. Animal PET imaging was also performed and relative uptake values in the thoracic aorta were compared between ApoE−/− and control mice. In humans, the kinetic characteristics and feasibility of 68Ga-NOTA-RGD PET were assessed in 4 patients with known coronary artery disease.

Results

In the tissue uptake study, the thoracic aorta showed higher uptake in ApoE−/− than in control mice with both 68Ga-NOTA-RGD and 18FDG (P < 0.001). On PET scans, the relative uptake values of the thoracic aorta were significantly higher in ApoE−/− with both 68Ga-NOTA-RGD (P = 0.024) and 18FDG (P = 0.038). In human PET, the appropriateness of reversible binding model and Logan plotting was clearly demonstrated. The aorta-to-jugular ratios were measured up to 1.25 and showed a tendency to correlate with the serum high-sensitivity C-reactive protein level (r = 0.899, P = 0.102).

Conclusions

68Ga-NOTA-RGD has potential as an in vivo atherosclerosis imaging agent. However, the lower imaging contrast and sensitivity of 68Ga-NOTA-RGD PET compared with 18FDG PET may be a limitation for clinical application.
Literature
1.
Hackett D, Davies G, Maseri A. Pre-existing coronary stenoses in patients with first myocardial infarction are not necessarily severe. Eur Heart J. 1988;9:1317–23.CrossRefPubMed
2.
Murabito JM, Evans JC, Larson MG, Levy D. Prognosis after the onset of coronary heart disease. An investigation of differences in outcome between the sexes according to initial coronary disease presentation. Circulation. 1993;88:2548–55.CrossRefPubMed
3.
4.
Ogawa M, Magata Y, Kato T, Hatano K, Ishino S, Mukai T, et al. Application of 18F-FDG PET for monitoring the therapeutic effect of antiinflammatory drugs on stabilization of vulnerable atherosclerotic plaques. J Nucl Med. 2006;47:1845–50.PubMed
5.
Tahara N, Kai H, Ishibashi M, Nakaura H, Kaida H, Baba K, et al. Simvastatin attenuates plaque inflammation: evaluation by fluorodeoxyglucose positron emission tomography. J Am Coll Cardiol. 2006;48:1825–31.CrossRefPubMed
6.
Arauz A, Hoyos L, Zenteno M, Mendoza R, Alexanderson E. Carotid plaque inflammation detected by 18F-fluorodeoxyglucose-positron emission tomography. Pilot study. Clin Neurol Neurosurg. 2007;109:409–12.CrossRefPubMed
7.
Tahara N, Kai H, Yamagishi S, Mizoguchi M, Nakaura H, Ishibashi M, et al. Vascular inflammation evaluated by [18F]-fluorodeoxyglucose positron emission tomography is associated with the metabolic syndrome. J Am Coll Cardiol. 2007;49:1533–9.CrossRefPubMed
8.
Potter K, Lenzo N, Eikelboom JW, Arnolda LF, Beer C, Hankey GJ. Effect of long-term homocysteine reduction with B vitamins on arterial wall inflammation assessed by fluorodeoxyglucose positron emission tomography: a randomised double-blind, placebo-controlled trial. Cerebrovasc Dis. 2009;27:259–65.CrossRefPubMed
9.
Burtea C, Laurent S, Murariu O, Rattat D, Toubeau G, Verbruggen A, et al. Molecular imaging of alpha v beta3 integrin expression in atherosclerotic plaques with a mimetic of RGD peptide grafted to Gd-DTPA. Cardiovasc Res. 2008;78:148–57.CrossRefPubMed
10.
Waldeck J, Hager F, Holtke C, Lanckohr C, von Wallbrunn A, Torsello G, et al. Fluorescence reflectance imaging of macrophage-rich atherosclerotic plaques using an alphavbeta3 integrin-targeted fluorochrome. J Nucl Med. 2008;49:1845–51.CrossRefPubMed
11.
Laitinen I, Saraste A, Weidl E, Poethko T, Weber AW, Nekolla SG, et al. Evaluation of alphavbeta3 integrin-targeted positron emission tomography tracer 18F-galacto-RGD for imaging of vascular inflammation in atherosclerotic mice. Circ Cardiovasc Imaging. 2009;2:331–8.CrossRefPubMed
12.
Jeong JM, Hong MK, Chang YS, Lee YS, Kim YJ, Cheon GJ, et al. Preparation of a promising angiogenesis PET imaging agent: 68 Ga-labeled c(RGDyK)-isothiocyanatobenzyl-1,4,7-triazacyclononane-1,4,7-triacetic acid and feasibility studies in mice. J Nucl Med. 2008;49:830–6.CrossRefPubMed
13.
Zhang X, Xiong Z, Wu Y, Cai W, Tseng JR, Gambhir SS, et al. Quantitative PET imaging of tumor integrin alphavbeta3 expression with 18F-FRGD2. J Nucl Med. 2006;47:113–21.PubMed
14.
Patsenker E, Popov Y, Stickel F, Schneider V, Ledermann M, Sagesser H, et al. Pharmacological inhibition of integrin alphavbeta3 aggravates experimental liver fibrosis and suppresses hepatic angiogenesis. Hepatology. 2009;50:1501–11.CrossRefPubMed
15.
Tahara N, Imaizumi T, Virmani R, Narula J. Clinical feasibility of molecular imaging of plaque inflammation in atherosclerosis. J Nucl Med. 2009;50:331–4.CrossRefPubMed
16.
Aziz K, Berger K, Claycombe K, Huang R, Patel R, Abela GS. Noninvasive detection and localization of vulnerable plaque and arterial thrombosis with computed tomography angiography/positron emission tomography. Circulation. 2008;117:2061–70.CrossRefPubMed
17.
Tawakol A, Migrino RQ, Bashian GG, Bedri S, Vermylen D, Cury RC, et al. In vivo 18F-fluorodeoxyglucose positron emission tomography imaging provides a noninvasive measure of carotid plaque inflammation in patients. J Am Coll Cardiol. 2006;48:1818–24.CrossRefPubMed
18.
Graebe M, Pedersen SF, Borgwardt L, Hojgaard L, Sillesen H, Kjaer A. Molecular pathology in vulnerable carotid plaques: correlation with [18]-fluorodeoxyglucose positron emission tomography (FDG-PET). Eur J Vasc Endovasc Surg. 2009;37:714–21.CrossRefPubMed
19.
Wu YW, Kao HL, Chen MF, Lee BC, Tseng WY, Jeng JS, et al. Characterization of plaques using 18F-FDG PET/CT in patients with carotid atherosclerosis and correlation with matrix metalloproteinase-1. J Nucl Med. 2007;48:227–33.PubMed
20.
Rominger A, Saam T, Wolpers S, Cyran CC, Schmidt M, Foerster S, et al. 18F-FDG PET/CT identifies patients at risk for future vascular events in an otherwise asymptomatic cohort with neoplastic disease. J Nucl Med. 2009;50:1611–20.CrossRefPubMed
21.
Jaffer FA, Libby P, Weissleder R. Molecular imaging of cardiovascular disease. Circulation. 2007;116:1052–61.CrossRefPubMed
22.
Moulton KS, Vakili K, Zurakowski D, Soliman M, Butterfield C, Sylvin E, et al. Inhibition of plaque neovascularization reduces macrophage accumulation and progression of advanced atherosclerosis. Proc Natl Acad Sci USA. 2003;100:4736–41.CrossRefPubMed
23.
Higuchi T, Bengel FM, Seidl S, Watzlowik P, Kessler H, Hegenloh R, et al. Assessment of alphavbeta3 integrin expression after myocardial infarction by positron emission tomography. Cardiovasc Res. 2008;78:395–403.CrossRefPubMed
24.
Haukkala J, Laitinen I, Luoto P, Iveson P, Wilson I, Karlsen H, et al. 68Ga-DOTA-RGD peptide: biodistribution and binding into atherosclerotic plaques in mice. Eur J Nucl Med Mol Imaging. 2009;36:2058–67.CrossRef
25.
Yang SJ, Kim S, Choi HY, Kim TN, Yoo HJ, Seo JA, et al. High-sensitivity C-reactive protein in the low- and intermediate-Framingham risk score groups: analysis with (18)F-fluorodeoxyglucose positron emission tomography. Int J Cardiol. 2013;163:277–81.CrossRefPubMed
Metadata
Title
Feasibility and kinetic characteristics of 68Ga-NOTA-RGD PET for in vivo atherosclerosis imaging
Authors
Jin Chul Paeng
Yun-Sang Lee
Jae Sung Lee
Jae Min Jeong
Ki-Bong Kim
June-Key Chung
Dong Soo Lee
Publication date
01-11-2013
Publisher
Springer Japan
Published in
Annals of Nuclear Medicine / Issue 9/2013
Print ISSN: 0914-7187
Electronic ISSN: 1864-6433
DOI
https://doi.org/10.1007/s12149-013-0757-x

Other articles of this Issue 9/2013

Annals of Nuclear Medicine 9/2013 Go to the issue

Original Article

Agreement between SPECT V/Q scan and CT angiography in patients with high clinical suspicion of PE

Commentary

The promise and limits of PET texture analysis

Original Article

Diagnostic usefulness of an amino acid tracer, α-[N-methyl-11C]-methylaminoisobutyric acid (11C-MeAIB), in the PET diagnosis of chest malignancies

Original Article

Quantitative CBF measurement using an integrated SPECT/CT system: validation of three-dimensional ordered-subset expectation maximization and CT-based attenuation correction by comparing with O-15 water PET

Letter to the Editor

Comment on Minamimoto: incidental focal FDG uptake in heart is a lighthouse for considering cardiac screening

Original Article

Evaluation of noise equivalent count parameters as indicators of adult whole-body FDG-PET image quality